ArticleAtherosclerosis2017
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Article in Atherosclerosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.The Journal of clinical investigation · 2022Pooled it
- Enhanced Prediction of Peripheral Artery Disease Using Plasma Proteomics Among Individuals Without Diabetes.Journal of the American Heart Association · 2026Article
- The role of suPAR and related proteins in kidney, heart diseases, and diabetes.The Journal of clinical investigation · 2026Review
- Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus.Molecules (Basel, Switzerland) · 2025Review
- An emerging role of inflammatory biomarker (suPAR) for prognostic evaluation of atrial fibrillation.Journal of arrhythmia · 2025Article
- Article
- A machine learning algorithm for peripheral artery disease prognosis using biomarker data.iScience · 2024Article
- Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.Current cardiology reports · 2023Review
- Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD.Kidney international reports · 2023Article
- Identification and validation of hub genes involved in foam cell formation and atherosclerosis developmentPeerJ · 2023Article
- Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease.The Journal of clinical investigation · 2022Article
- Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.Diabetes care · 2022Observational
- RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.Biochimica et biophysica acta. Molecular basis of disease · 2021Article
- Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.Journal of clinical medicine research · 2021Review
- Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.Vascular medicine (London, England) · 2021Article
- A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.European journal of heart failure · 2020Article
- Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.Journal of the American Heart Association · 2020Article
- Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.Journal of the American Heart Association · 2020Article
- Deficiency of Urokinase Plasminogen Activator May Impair β Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.Molecules (Basel, Switzerland) · 2019Article
- Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.International journal of cardiology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsCirculating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study.
methodsSuPAR levels were measured in 5810 patients (mean age 63 years, 63% male, 77% with obstructive coronary artery disease [CAD]) undergoing cardiac catheterization. The presence of PAD (n = 967, 17%) was classified as carotid (36%), lower/upper extremities (30%), aortic (15%) and multisite disease (19%). Multivariable logistic and Cox regression models were used to determine independent predictors of prevalent PAD and outcomes including all-cause death, cardiovascular death and PAD-related events after adjustment for age, gender, race, body mass index, smoking, diabetes, hypertension, hyperlipidemia, renal function, heart failure history, and obstructive CAD.
resultsPlasma suPAR levels were 22.5% (p < 0.001) higher in patients with PAD compared to those without PAD. Plasma suPAR was higher in patients with more extensive PAD (≥2 compared to single site) p < 0.001. After multivariable adjustment, suPAR was associated with prevalent PAD; odds ratio (OR) for highest compared to lowest tertile of 2.0, 95% CI (1.6-2.5) p < 0.001. In Cox survival analyses adjusted for clinical characteristics and medication regimen, suPAR (in the highest vs. lowest tertile) remained an independent predictor of all-cause death [HR 3.1, 95% CI (1.9-5.3)], cardiovascular death [HR 3.5, 95% CI (1.8-7.0)] and PAD-related events [HR = 1.8, 95% CI (1.3-2.6) p < 0.001 for all].
conclusionsPlasma suPAR level is predictive of prevalent PAD and of incident cardiovascular and PAD-related events. Whether SuPAR measurement can help screen, risk stratify, or monitor therapeutic responses in PAD requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.